Dogwood Narrows Q3 Loss to $4.9M as Halneuron Phase 2b Readout Lands This Month
DWTX sits 22% above its 52-week low of $0.901.
Summary
Dogwood posted a Q3 2026 net loss of $4.9M, or $0.14 per share, against $15.7M, or $8.20 per share, a year earlier. The swing is mostly optics: Q3 2025 carried $12.0M of acquired IPR&D expense, and R&D fell to $3.3M from $14.5M for the same reason rather than from a real cut in ongoing development spend. The number that matters is the Halneuron Phase 2b top-line readout for chemotherapy-induced neuropathic pain, now due this month after enrollment completed in September. Cash is the other constraint — the August 10-Q carried a going concern warning with runway only into Q4 2026, and the $5M Sealbond placement at $1.22 that closed in late October extends it only through March 2027. With a micro-cap valuation, the Phase 2b result will decide whether the program advances to Phase 3 or the company needs another raise.
At the time of this announcement, DWTX was trading at $1.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.4M. The 52-week trading range was $0.90 to $7.04. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.